Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Noelle Rolle

Rheumatology Augusta, GA Medical Doctor

NPI 1003249194 CMS profile 4221156

1447 Harper St Fl 2, Augusta, GA 30912

Open in the dashboard

General payments

$9,384

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Noelle Rolle of Augusta, GA is reported in the CMS Open Payments database as having received $9,384 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,438 38
2024 General $1,787 48
2023 General $2,930 28
2022 General $325 12
2021 General $1,113 37
2020 General $542 26
2019 General $1,250 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Noelle Rolle
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Noelle Rolle were reported at $1,438. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Noelle Rolle Rheumatology median Middle half National median
2019 $1,250 $744 $153–$2,687 $163
2020 $542 $462 $98–$2,027 $114
2021 $1,113 $531 $101–$2,153 $132
2022 $325 $627 $125–$2,303 $149
2023 $2,930 $741 $145–$2,524 $160
2024 $1,787 $830 $166–$2,660 $164
2025 $1,438 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,546 22 payments
  2. AbbVie, Inc. $1,075 28 payments
  3. Amgen Inc. $977 30 payments
  4. Genzyme Corporation $803 9 payments
  5. Aurinia Pharma U.S., Inc. $501 12 payments
  6. Pfizer Inc. $448 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $437 14 payments
  8. Lilly USA, LLC $355 12 payments
  9. AstraZeneca Pharmaceuticals LP $349 16 payments
  10. UCB, Inc. $312 8 payments
  11. Other $1,580 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,165 215 payments
  2. Consulting Fee $1,950 1 payment
  3. Education $269 4 payments
Products named General payments · program years 2019–2025
  1. BENLYSTA $2,360 19 payments
  2. KEVZARA $865 9 payments
  3. LUPKYNIS $501 12 payments
  4. RINVOQ $448 12 payments
  5. XELJANZ $354 15 payments
  6. OFEV $329 11 payments
  7. TALTZ $328 11 payments
  8. EVENITY $318 10 payments
  9. TREMFYA $314 8 payments
  10. COSENTYX $234 5 payments
  11. Other $3,541 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

493

Median for Internal Medicine: 777

Drug cost

$426,395

Median for Internal Medicine: $73,373

Branded share of claims

30.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 21 $131,283
Cosentyx Sensoready Pen Secukinumab Brand 16 $110,032
Humira(Cf) Pen Adalimumab Brand 12 $91,572
Xeljanz Tofacitinib Citrate Brand 15 $87,270
Hydroxychloroquine Sulfate Generic 95 $1,821
Methotrexate Methotrexate Sodium Brand 86 $1,205
Colchicine Generic 22 $1,143
Azathioprine Generic 12 $610
Leflunomide Generic 14 $367
Allopurinol Generic 38 $362

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$12,820

Medicare's payments for the services billed

Medicare patients

72

Average age 69

Services billed

219

54 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Osteoporosis 31%
Chronic kidney disease 29%
Depression 28%
Ischemic heart disease 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEVZARA
  • GENZYME CORPORATION $268
  • SANOFI-AVENTIS U.S. LLC $99
$367 — —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $171
$171 — —
SKYRIZI
  • AbbVie, Inc. $163
$163 — —
RINVOQ
  • AbbVie, Inc. $156
$156 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record